InsidersTradesSigma
Total declarations
Companies
▲ Purchases (28 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
28
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Hayes Anthony, Chief Executive Officer. Director active across 2 companies, notably AIkido Pharma Inc.. Cumulatively, 34 disclosures have been recorded. Split: 28 buys · 0 sell. Total volume traded: €817k. Activity tracked since 3 May 2021. The latest transaction was filed on 29 May 2024 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations34 total
15,000 sharesCommon StockSEC:0001213900-25-040168:0
154,559 sharesCommon StockSEC:0001013762-25-002158:0
500,000 sharesCommon StockSEC:0001213900-25-015820:0
288,184 sharesCommon StockSEC:0001213900-25-012975:0
Ideal exit: 7 Nov 2025 (T+270)
309,118 sharesCommon StockSEC:0001213900-25-000790:0
154,559 sharesCommon StockSEC:0001213900-24-052468:0
1,158 shares@ US$2.250.8% of flowCommon StockSEC:0001213900-24-048446:0
Ideal exit: 23 Feb 2025 (T+270)
3,944 shares@ US$2.62153.2% of flowCommon StockSEC:0001213900-24-031175:0
Ideal exit: 30 Dec 2024 (T+270)
70,000 shares@ US$2.002442.2% of flowCommon StockSEC:0001213900-23-097830:0
Ideal exit: 15 Sept 2024 (T+270)
2,000 shares@ US$2.00121.2% of flowCommon StockSEC:0001213900-23-095707:0
Ideal exit: 7 Sept 2024 (T+270)
1,323 shares@ US$2.08990.8% of flowCommon StockSEC:0001213900-23-090218:0
Ideal exit: 18 Aug 2024 (T+270)
2,500 shares@ US$1.96631.5% of flowCommon StockSEC:0001213900-23-088462:0
Ideal exit: 12 Aug 2024 (T+270)
2,500 shares@ US$1.92991.5% of flowCommon StockSEC:0001213900-23-087634:0
Ideal exit: 10 Aug 2024 (T+270)
7,500 shares@ US$2.499611.9% of flowCommon StockSEC:0001213900-23-078533:0
Ideal exit: 16 Jun 2024 (T+270)
2,000 shares@ US$2.74683.2% of flowCommon StockSEC:0001213900-23-077016:0
Ideal exit: 9 Jun 2024 (T+270)
2,000 shares@ US$2.85891.7% of flowCommon StockSEC:0001213900-23-070962:0
Ideal exit: 19 May 2024 (T+270)
2,000 shares@ US$2.93991.8% of flowCommon StockSEC:0001213900-23-068954:0
Ideal exit: 12 May 2024 (T+270)
1,319 shares@ US$2.87461.2% of flowCommon StockSEC:0001213900-23-049251:0
Ideal exit: 10 Mar 2024 (T+270)
506 shares@ US$2.88590.4% of flowCommon StockSEC:0001213900-23-048915:0
Ideal exit: 9 Mar 2024 (T+270)
2,000 shares@ US$2.751.7% of flowCommon StockSEC:0001213900-23-042860:0
Ideal exit: 18 Feb 2024 (T+270)
2,000 shares@ US$2.76891.7% of flowCommon StockSEC:0001213900-23-040988:0
Ideal exit: 11 Feb 2024 (T+270)
2,000 shares@ US$2.76731.7% of flowCommon StockSEC:0001213900-23-040652:0
Ideal exit: 10 Feb 2024 (T+270)
30,000 shares@ US$3.438131.1% of flowCommon StockSEC:0001213900-23-027233:0
Ideal exit: 30 Dec 2023 (T+270)
4,500 shares@ US$3.691.6% of flowCommon StockSEC:0001213900-22-080305:0
Ideal exit: 10 Sept 2023 (T+270)
5,000 shares@ US$3.6971.8% of flowCommon StockSEC:0001213900-22-079914:0
Ideal exit: 9 Sept 2023 (T+270)
25 of 34 declarations
About Hayes Anthony
Anthony Hayes is the Chief Executive Officer of AIkido Pharma Inc. He is responsible for the strategic direction of the company, overseeing operations and resource management. With a strong background in the pharmaceutical industry, he is committed to promoting innovation and developing treatments that meet patient needs. His leadership is essential for AIkido Pharma's growth and sustainability.
